Evaluation of actual traceability of labile blood products from patients' records

被引:7
|
作者
Ingrand, P [1 ]
Salmi, LR
Benz-Lemoine, E
Dupuis, M
机构
[1] Ctr Hosp Univ Miletrie, Dept Med Informat, F-86021 Poitiers, France
[2] Inst Sante Publ Epidemiol & Dev, Ctr Natl Hemovigilance, Bordeaux, France
[3] Ctr Hosp Univ Poitiers, Unite Hemovigilance, Poitiers, France
[4] Etab Transfus Sanguine Poitou Charentes, Poitiers, France
关键词
evaluation; haemovigilance; medical records; traceability; transfusion;
D O I
10.1016/S1246-7820(99)80004-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The traceability of blood products is an essential part of haemovigilance and transfusion safety. A pilot survey assessed the actual traceability by analysing transfusion information collected from medical records of a representative sample of 390 labile blood products transfused in a French university hospital. Transfusion and distribution forms were missing in 2.3% and 6.9% respectively. Availability and validity of transfusion information varied according to the nature of the expected information, elements of patients' records and types of wards. The location where the transfusion was performed was false or ambiguous in 38% of cases in surgery. Crude traceability, evaluated by the feedback of validated distribution forms, was estimated at 85.2% whereas actual traceability was estimated at 81.9% (SD 1.7%). High availability (98.7%) of at least one of the two sheets of the distribution form in medical records, or in the blood bank, revealed that a significant improvement of traceability should come from a better compliance to the rules of information transmission. The actual traceability differed significantly according to clinical services (worse in surgery) and was lower in case of autologous or absence of previous transfusion. An analysis of markers of good traceability should suggest efficient evolution of organization and information systems. This pilot study shows the relevance and feasibility of this kind of survey which could interestingly be performed on a large national representative random sample. (C) 1998 Elsevier, Paris.
引用
收藏
页码:397 / 407
页数:11
相关论文
共 50 条
  • [1] Traceability of blood products:: definition, regulations, evaluation and perspectives
    Pélissier, E
    Nguyen, L
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2000, 7 : 72S - 74S
  • [2] Qualitative evaluation of blood products records in a hospital
    Lartigue, B.
    Catillon, E.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2012, 19 (01) : 11 - 16
  • [3] Labile Blood Products in 2016
    Swiech, A.
    Ausset, S.
    REANIMATION, 2016, 25 (05): : 475 - 483
  • [4] Evaluation of blood products traceability in the Midi-Pyrenees area in France
    Verret, C
    Mathoulin-Pelissier, S
    Courbil, R
    Perez, P
    Destruel, F
    Roubinet, F
    Rech, H
    Vidal, I
    Salmi, LR
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 1998, 5 (04) : 275 - 282
  • [5] Traceability of labile blood products in Morocco: Experience of the Ibn-Sina hospital of Rabat between 1999 and 2010
    Ouadghiri, S.
    Atouf, O.
    Brick, C.
    Benseffaj, N.
    Essakalli, M.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2012, 19 (01) : 1 - 4
  • [6] LEUKOCYTE DEPLETION IN LABILE BLOOD PRODUCTS
    GEROTA, J
    CAVALIER, J
    MASSE, M
    WALLER, W
    BIDET, ML
    REVUE FRANCAISE DE TRANSFUSION ET IMMUNO-HEMATOLOGIE, 1987, 30 (02): : 109 - +
  • [7] Pathogen inactivation of labile blood products
    Bopp, MKF
    Morell, A
    Indrak, K
    Parkkinen, J
    Mertens, H
    Mohr, H
    Colamartino, P
    Stanescu, I
    Oyonarte, S
    Delaney, FM
    Padilla, A
    TRANSFUSION MEDICINE, 2001, 11 (03) : 149 - 175
  • [8] Pathogen inactivation in labile blood products
    Naegelen, C.
    Isola, H.
    Dernis, D.
    Maurel, J. -P.
    Tardivel, R.
    Bois, S.
    Vignoli, C.
    Cazenave, J. -P.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2009, 16 (02) : 179 - 189
  • [9] Viral inactivation of labile blood products
    Follea, G
    Herve, P
    Andreu, G
    Bidet, JM
    Boudard, D
    Dazey, B
    Noel, L
    Piquet, Y
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 1996, 3 (02) : 113 - 123
  • [10] Distribution and delivery of labile blood products
    Roubinet, Francis
    HEMATOLOGIE, 2010, 16 (04): : 302 - 309